SARmont

Dr. John Talley has been appointed chief scientific officer of SARmont, a provider of medicinal chemistry services. Dr. Talley will oversee all drug design and optimization projects for clients to identify high quality and proprietary investigational new drug (IND) lead candidates. Randy Weiss will serve as SARmont’s first president and chief executive officer.

“SARmont partners with pharmaceutical companies, venture capital firms and research institutions to help bring promising new drugs to the market,” said Dr. Talley. “By helping our clients overcome obstacles of preclinical pharmaceutical research, we increase the probability of success.”

SARmont provides drug design and lead optimization services to help clients streamline and accelerate the drug design process. SARmont’s management team also includes Dr. Eduardo Martinez, director of operations, and Dr. Rick Ryan, president of business development.

“SARmont is a trusted strategic partner that provides medicinal chemistry design and lead optimization services that put the focus on efficient and cost-effective success,” said Dr. Ryan. “In an increasingly competitive market, our unique partnership approach ensures that SARmont clients own any intellectual property that’s generated to help them institutionalize that knowledge, and we help develop the IP strategy.”